Avacta Group Plc Preliminary Q4 2024 Earnings Conference Call June 6, 2025 6:00 AM ET
Company Participants
Brian M. Hahn – Chief Financial Officer
Christina Marie Coughlin – CEO, Interim Chief Medical Officer and Director
Operator
Good morning, and welcome to the Avacta Group Plc Investor Presentation. [Operator Instructions] Due to the high attendance on today’s call, the company may not be in a position to answer every question received in the meeting itself. However, the company can review the questions submitted today and publish responses where it’s appropriate to do so.
Before we begin, I’d like to submit the following poll.
I’d now like to hand you over to CEO, Christina Coughlin. Good morning.
Christina Marie Coughlin
Good morning, and thank you for having us. I’m joined today by our Chief Financial Officer, Brian Hahn, and we will be presenting the fiscal year 2024 preliminary results for Avacta Therapeutics. Let’s jump in. We will be making forward-looking statements, and our disclaimer is noted here on the second slide.
Let me start with a few of the highlights for Avacta. The company has essentially over the last year, undergone a complete transformation, and we are now positioned as a pure-play oncology biopharmaceutical company. When we joined you last year, this was a joined-up diagnostics and therapeutics company. And over the course of this last year, with the divestment of one of the aspects of the diagnostics company with the second one coming, we are now focused on our proprietary pre|CISION peptide drug conjugate platform within the company and are poised to move this into the next stage.
Let me tell you a little bit about that and how we are accomplishing that. Our first entry into the clinic and really the program that created all the buzz and all the excitement
Read the full article here